| 摘要 |
The invention relates to inhibitors of the transcription factor STAT-1, to their use as therapeutic agents and to their use for the prevention or thera py of: cardiovascular complications such as restenosis after percutaneous angioplasty or the stenosis of vein bypasses; the graft-versus-host-reaction ; ischaemia/reperfusion damage during surgery or organ transplant operations; immunological hypersensitivity reactions, in particular allergic rhinitis or allergies to medicaments and foodstuffs, in particular urticaria and coeliac disease (sprue); contact eczema and immunocomplex diseases, in particular alveolitis, arthritis, glomerulonephritis and vasculitis allergica; inflammatory diseases of the cartilage and bone, in particular arthrosis, gout, ostitis and osteomyelitis; polyneuritis and acute or subacute, infecti on- induced or post-infective inflammatory diseases, in particular bronchitis, endocarditis, hepatitis, myocarditis, nephritis, pericarditis, peritonitis a nd pancreatitis, including septic shock.
|
